Loading…
← CockpitCompetitor Analysis › 688016.SS Shanghai MicroPort Endovascular MedTech Co., Ltd Class AOpen in the cockpit ↗

Shanghai MicroPort Endovascular MedTech Co., Ltd Class A688016.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

MicroPort Group unit making stent grafts and devices for treating aortic and peripheral vascular disease.

≈ A Chinese Medtronic Endovascular/Gore AorticMomentum strong 73
Mkt cap
$1.55B
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$18.6M
20-day average traded
Fwd P/E
16.4×
forward earnings
ROIC−WACC
+16.8 pp
WACC 7.5%
Hurdle
-21 pp
Req g minus delivered
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥84.05
1D-2.8%
1W-2.4%
1M-0.3%
3M-10.7%
6M-18.9%
YTD-8.3%
1Y-15.4%
ATR %2.5%
52w lowhigh27.5% off high

What Shanghai MicroPort Endovascular MedTech does

MicroPort Group unit making stent grafts and devices for treating aortic and peripheral vascular disease.

Sells devices to hospitals, mostly through distributors, and surgeons' training on each device drives repeat use. State-run bulk-purchase schemes have pushed down prices in other implant categories. It is part of the MicroPort group and is listed separately.

In one line: A Chinese Medtronic Endovascular/Gore Aortic.

Products and services

  • Aortic stent grafts
  • Peripheral vascular devices
  • Vascular access products

Customers

  • Vascular surgeons/hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Endovascular/aortic stent grafts

What could go right

  • China aortic disease treatment-volume growth

What could go wrong

  • Volume-based procurement price cuts

Moat: narrow (IP / patents, regulatory licence). Device approvals and physician training favor an established device maker.

Headquarters: Shanghai, China · Employees: 822

Named competitors

Shanghai MicroPort Endovascular MedTech at a glance

Size Shanghai MicroPort Endovascular MedTech (688016.SS) is a China Health Care company (Medical Specialties) with a market value of $1.55B, the 1473rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥84.05 on 18 Nov 2026.

Performance Over six months the shares fell 18.9%, against +1.9% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.

Growth Revenue grew 16.2% over the last twelve months (peer median +6.6%); the operating margin is 44.2% (peer median 8.2%).

Valuation It trades at 16.4× forward earnings against a peer median of 24.5× (5th cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -21 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.8 points above its cost of capital (7.5% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 102688016.SS 85
Six months, rebased to 100: Shanghai MicroPort Endovascular MedTech against the median of its 20 peers (local-currency closes).

Shanghai MicroPort Endovascular MedTech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.45BCN¥1.34BCN¥1.20BCN¥1.18BCN¥889M
Revenue growth—+12%+2%+32%—
Gross profitCN¥1.11BCN¥908MCN¥844MCN¥882MCN¥651M
EBITDAn/aCN¥665MCN¥578MCN¥578MCN¥417M
Net incomeCN¥583MCN¥563MCN¥502MCN¥492MCN¥357M
Free cash flowCN¥254MCN¥286MCN¥191MCN¥381MCN¥53.2M
Capital expenditureCN¥249MCN¥303MCN¥213MCN¥190MCN¥294M
Total debtCN¥14.0MCN¥15.0MCN¥40.9MCN¥35.7MCN¥41.2M

Quarterly statements and history in the cockpit →

Shanghai MicroPort Endovascular MedTech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%6849ENOVVITR6885313010876699BFLYELN300049300298PRCT8086CNMDINSPKMTSEMBLA301363LMATCHEMM688016.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Shanghai MicroPort Endovascular MedTech is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×6849ENOVVITR6885313010876699ELN3000498086CNMDINSPXRAYEMBLA301363LMATCHEMM688016.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shanghai MicroPort Endovascular MedTech is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%6849ENOVVITR3010876699ELN300049300298CNMDINSPEMBLA301363LMATCHEMM688016.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Shanghai MicroPort Endovascular MedTech is the large dot.

Shanghai MicroPort Endovascular MedTech competitors and peer comparison

Head to head with its named competitors (688016.SS vs MDT vs 4543.T vs 300760.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Shanghai MicroPort Endovascular MedTech 688016.SS$1.55B-19%+16%44%16.4×2.7%
Medtronic MDT$129B+30%+10%20%16.8×9.1%
Terumo 4543.T$24.0B+32%+15%17%27.8×8.8%
Shenzhen Mindray Bio-Medical Electronics 300760.SZ$33.6B+15%+5%28%27.3×1.0%

How Shanghai MicroPort Endovascular MedTech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shanghai MicroPort Endovascular MedTech against its 20 peers (data as of 18 Nov 2026)
Measure688016.SSPeer medianRank in peer set
1-month return-0.3%-0.9%11th highest of 21
6-month return-18.9%+1.9%5th lowest of 21
Distance from 52-week high-27.5%-24.8%10th lowest of 21
Revenue growth (TTM)+16.2%+6.6%7th highest of 21
Operating margin44.2%8.2%2nd highest of 21
Forward P/E16.4×24.5×5th cheapest of 18
Growth the price implies (Req g, 7 yrs)2.7%11.2%3rd least demanding of 16
Growth delivered (Del g)+23.4%+12.7%3rd highest of 16
Hurdle (Req g minus delivered)-20.7 pp-0.3 pp2nd least demanding of 16
ROIC minus cost of capital+16.8 pp-0.1 pp4th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
Inspire Medical Systems INSPUnited States$1.68B+32%0%2%41.3×28.7%+51.2%
Kestra Medical Technologies KMTSUnited States$1.69B+36%+61%-134%n/an/an/a
DENTSPLY SIRONA XRAYUnited States$1.69B-13%-1%5%6.8×11.2%+1.9%
Embla Medical hf EMBLA.CODenmark$1.72B+1%+6%14%17.2×-1.9%+8.3%
Mehow Innovative 301363.SZChina$1.72B-36%+10%21%34.2×16.4%+12.9%
LeMaitre Vascular LMATUnited States$1.73B-25%+12%28%24.5×2.9%+14.0%
ChemoMetec A/S CHEMM.CODenmark$1.77B+107%+3%49%46.7×19.4%+12.7%

Questions

Who are Shanghai MicroPort Endovascular MedTech's main competitors?
Named competitors: Medtronic (MDT), W.L. Gore (private) (private or unlisted), Terumo Aortic (4543.T), Lifetech Scientific (300760.SZ). The cockpit's measured peer set (industry) also includes Nihon Kohden (6849.T), Enovis (ENOV), Vitrolife (VITR.ST), Wuxi Unicomp Technology (688531.SS), Cofoe Medical Technology (301087.SZ), Angelalign Technology (6699.HK).
Is Shanghai MicroPort Endovascular MedTech expensive compared with its peers?
On forward p/e it trades at 16.4× against a peer median of 24.5×, 5th cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -21 pp: the price already allows for a slowdown.
How has Shanghai MicroPort Endovascular MedTech stock performed?
Over six months to 18 Nov 2026 the shares returned -18.9% against +1.9% for the median peer; over one year -15.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.